Journal Mobile Options
Table of Contents
Vol. 127, No. 1, 2012
Issue release date: December 2011
Section title: Original Paper
Acta Haematol 2012;127:1–6
(DOI:10.1159/000330948)

Imatinib Mesylate Therapy Induces Reduction in Neutrophil Gelatinase-Associated Lipocalin Serum Levels and Increase in Leptin Concentrations in Chronic Myeloid Leukemia Patients in Molecular Remission

Alonci A.a · Allegra A.a · Russo S.a · Penna G.a · Bellomo G.a · D’Angelo A.a · Campo S.b · Cannavò A.a · Centorrino R.a · Musolino C.a
aDivision of Hematology, and bDepartment of Biochemical, Physiological and Nutritional Sciences, Medicinal Chemistry Section, University of Messina, Messina, Italy

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 5/23/2011 9:58:37 AM
Accepted: 7/13/2011
Published online: 10/4/2011
Issue release date: December 2011

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: http://www.karger.com/AHA

Abstract

The aim of the present study was to determine serum levels of neutrophil gelatinase-associated lipocalin (NGAL) and leptin in patients with chronic myeloid leukemia (CML) at diagnosis and after imatinib therapy when patients achieved a complete molecular remission. The study was conducted on 22 patients with CML in the chronic phase and 10 healthy subjects. The median serum NGAL levels in CML patients at diagnosis were significantly higher compared to age-matched controls. After imatinib therapy, all patients achieved complete molecular remission and NGAL levels decreased and were found significantly lower with respect to the baseline. No significant correlations were found between NGAL levels and other disease parameters. Before imatinib therapy, the median blood leptin levels were not significantly different from those of controls. After therapy with imatinib, all patients in molecular remission presented an increase in leptin levels. Future research is eagerly awaited as it may demonstrate the real role of NGAL and leptin in the onset and progression of CML.

© 2011 S. Karger AG, Basel


  

Author Contacts

Prof. Caterina Musolino
University of Messina
Via Colapesce 20
IT–98100 Messina (Italy)
Tel. +39 090 221 2355, E-Mail cmusolino@unime.it

  

Article Information

Received: May 23, 2011
Accepted after revision: July 13, 2011
Published online: October 4, 2011
Number of Print Pages : 6
Number of Figures : 1, Number of Tables : 0, Number of References : 36

  

Publication Details

Acta Haematologica

Vol. 127, No. 1, Year 2012 (Cover Date: December 2011)

Journal Editor: Ben-Bassat I. (Qiryat-Ono)
ISSN: 0001-5792 (Print), eISSN: 1421-9662 (Online)

For additional information: http://www.karger.com/AHA


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 5/23/2011 9:58:37 AM
Accepted: 7/13/2011
Published online: 10/4/2011
Issue release date: December 2011

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: http://www.karger.com/AHA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.